CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Q1 2025 Earnings Call Transcript April 29, 2025 Pfizer Inc. beats earnings expectations. Reported EPS is $0.92, expectations ...

CEOs have been grilled on tariffs and their impact on business and consumers' wallets in recent earnings calls and interviews ...

Pfizer’s chief executive, Albert Bourla, told investors that the uncertainty surrounding President Donald Trump’s proposed tariffs on imported medicines is ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

David Denton; Executive Vice President, Chief Financial Officer; Pfizer Inc Aamir Malik; Executive Vice President, Chief US Commercial Officer; Pfizer Inc Alexandre De Germay; Executive Vice President ...

Entering trading on Monday, the S&P 500 has declined around 6% since the start of the year. Three stocks that are down over ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...